Platinum Priority – Prostate Cancer

Newcastle University ePrints eprint.ncl.ac.uk Johnston TJ, Shaw GL, Lamb AD, Parashar D, Greenberg D, Xiong T, Edwards AL, Gnanapragasam V, Holding P, Herbert P, Davis M, Mizielinsk E, Lane JA, Oxley J, Robinson M, Mason M, Staffurth J, Bollina P, Catto J, Doble A, Doherty A, Gillatt D, Kockelbergh R, Kynaston H, Prescott S, Paul A, Powell P, Rosario D, Rowe E, Donovan JL, Hamdy FC, Neal DE. Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial. European Urology 2017, 71(3), 381-388.

[1]  A. Armstrong,et al.  Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  K. Muir,et al.  Changing presentation of prostate cancer in a UK population – 10 year trends in prostate cancer risk profiles in the East of England , 2013, British Journal of Cancer.

[3]  C. Parker,et al.  Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms. , 2013, European urology.

[4]  I Syndikus,et al.  Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.

[5]  A. Ravaud,et al.  Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. , 2013, The Lancet. Oncology.

[6]  F. Saad,et al.  Abiraterone in metastatic prostate cancer without previous chemotherapy. , 2013, The New England journal of medicine.

[7]  P. Maté Mate.  [Radical prostatectomy versus observation for localized prostate cancer]. , 2013, Revista clinica espanola.

[8]  F. Saad,et al.  Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. , 2012, European journal of cancer.

[9]  I. Thompson,et al.  Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346). , 2012, The Journal of urology.

[10]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[11]  J. Gohagan,et al.  Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. , 2012, Journal of the National Cancer Institute.

[12]  M. Parmar,et al.  Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial , 2011, The Lancet.

[13]  F. Hamdy,et al.  Prostate‐specific antigen testing rates remain low in UK general practice: a cross‐sectional study in six English cities , 2011, BJU international.

[14]  Rosalia Viterbo,et al.  Long‐term survival after radical prostatectomy versus external‐beam radiotherapy for patients with high‐risk prostate cancer , 2011, Cancer.

[15]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[16]  M. Carducci,et al.  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study , 2011, The Lancet.

[17]  Hans Garmo,et al.  Radical prostatectomy versus watchful waiting in early prostate cancer. , 2005, The New England journal of medicine.

[18]  F. Montorsi,et al.  A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988-2006. , 2011, European urology.

[19]  J. Machiels,et al.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial , 2010, The Lancet.

[20]  P. Kantoff,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.

[21]  Naoto T. Ueno,et al.  Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST , 2010, Journal of Cancer.

[22]  F. Hamdy,et al.  Population‐based prostate‐specific antigen testing in the UK leads to a stage migration of prostate cancer , 2009, BJU international.

[23]  M. Parmar,et al.  Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials , 2009, The Lancet. Oncology.

[24]  C. Tangen,et al.  Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  S. Fosså,et al.  Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial , 2009, The Lancet.

[26]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[27]  M. Parmar,et al.  STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer--a multi-arm multi-stage randomised controlled trial. , 2008, Clinical oncology (Royal College of Radiologists (Great Britain)).

[28]  M. Parmar,et al.  Speeding up the Evaluation of New Agents in Cancer , 2008, Journal of the National Cancer Institute.

[29]  L. Holmberg,et al.  Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. , 2008, Journal of the National Cancer Institute.

[30]  R de Crevoisier,et al.  The postchemotherapy PSA surge syndrome. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  F. Hamdy,et al.  Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. , 2008, The Lancet. Oncology.

[32]  Susan Halabi,et al.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  F. Saad,et al.  Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases. , 2007, Clinical genitourinary cancer.

[34]  I. Tannock,et al.  Analysis of prostate-specific antigen decline as a surrogate for overall survival in metastatic hormone-refractory prostate cancer (HRPC) , 2007 .

[35]  C. Tangen,et al.  Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  C. Tangen,et al.  Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. , 2006, Journal of the National Cancer Institute.

[37]  P. Carroll,et al.  20-year outcomes following conservative management of clinically localized prostate cancer , 2005 .

[38]  Marc A Pfeffer,et al.  Cardiovascular Risk Associated With Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention , 2005, The New England journal of medicine.

[39]  J. Damber.  Endocrine therapy for prostate cancer , 2005, Acta oncologica.

[40]  C. Tangen,et al.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.

[41]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[42]  S. Moss,et al.  Rates of prostate‐specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: a cross‐sectional study , 2004, BJU international.

[43]  M. Parmar,et al.  A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). , 2003, Journal of the National Cancer Institute.

[44]  E. Bleecker,et al.  Association between genetic polymorphisms in the prostate-specific antigen gene promoter and serum prostate-specific antigen levels. , 2003, Journal of the National Cancer Institute.

[45]  D Gillatt,et al.  Prostate Testing for Cancer and Treatment (ProtecT) feasibility study. , 2003, Health technology assessment.

[46]  P. Kantoff,et al.  Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  F. Saad,et al.  A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. , 2002, Journal of the National Cancer Institute.

[48]  G. Andriole,et al.  The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma , 2000, Cancer.

[49]  H. Scher,et al.  Clinical states in prostate cancer: toward a dynamic model of disease progression. , 2000, Urology.

[50]  B. Freidlin,et al.  Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  A W Partin,et al.  Natural history of progression after PSA elevation following radical prostatectomy. , 1999, JAMA.

[52]  M. Egorin,et al.  Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy. , 1995, Journal of Clinical Oncology.

[53]  H. Rao.  Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients , 1995, The Lancet.

[54]  H I Scher,et al.  Bone metastases: improving the therapeutic index. , 1994, Seminars in oncology.

[55]  M Mazumdar,et al.  Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.